Objective: Androgen deprivation therapy (ADT) puts patients at an increased risk of developing osteoporosis. Assessment of bone mineral density (BMD) is most commonly performed by dual energy X-ray absorptiometry (DXA). Alternative ways of estimating BMD, such as quantitative ultrasound (QUS) measurement of the heel, are explored as DXA is expensive, non-portable and uses ionising radiation. We therefore investigated the diagnostic value of QUS as compared with DXA in patients commencing ADT.Methods: In this cross-sectional study of 60 patients with prostate cancer who were about to start ADT, BMD was measured with DXA and QUS. The fracture risk score, as implemented by the Dutch National Osteoporosis Guideline, was also measured.Results: No significant correlations were found between the separate DXA T scores and worst DXA T score, and the QUS T scores. Correlations between DXA T scores/QUS scores and fracture risk score were also non-significant. If QUS had been used as a screening tool, with a threshold of T ≤ −0.5 to perform DXA, then relevant osteopenia/ osteoporosis (worst DXA T score ≤ −2.0) would have been missed in 1/18 (5.6%) patients. The negative predictive value is 0.95. Using QUS as a screening test prior to DXA and a QUS threshold T score ≤ −0.5 would avoid 21 (35%) DXA scans at the cost of missing one (5.6%) case.Conclusion: QUS testing cannot replace DXA scans fully as a diagnostic test. However, QUS can be incorporated as triage test prior to DXA to reduce the need for unnecessary DXA scans and the associated costs.

Androgen deprivation therapy, Bone mineral density, Dual energy x-ray absorptiometry, Osteoporosis, Quantitative ultrasound
hdl.handle.net/1765/90613
The Netherlands Journal of Medicine
Erasmus School of Health Policy & Management (ESHPM)

van Casteren-Messidoro, C, Huisman, A.M, Birnie, E, van Gelder, M, Geijn, F.E, & Hamberg, A.P. (2014). Quantitative ultrasound of the heel as triage test to measure bone mineral density compared with dual energy X-ray absorptiometry in men with prostate cancer commencing with androgen deprivation therapy. The Netherlands Journal of Medicine, 72(10), 528–532. Retrieved from http://hdl.handle.net/1765/90613